PSYCH: The Psychedelics as Medicine Report is the first of Prohibition Partners market-leading intelligence reports to focus solely on psychedelic compounds and their potential. Specifically, the report concentrates on the use of psychedelic substances as medicines administered within clinical settings. The consumption of psychedelics outside of a clinical setting, whether for recreational or spiritual purposes, falls outside the scope of this first edition of the report.
The Psychedelics as Medicine Report presents detailed profiles on all the major psychedelic compounds which demonstrate therapeutic promise, and offers expert analysis of the current worldwide regulatory frameworks, clinical trial status, and commercial opportunities associated with these compounds.
In addition, the report features exclusive full-length interviews with some of the fields most prominent scientific minds and industry trailblazers, and highlights the key areas for development moving forward.
Psychedelics refers to a large number of different compounds, which as a group are characterised by their common ability to elicit hallucinogenic effects on a user. Most psychedelics are believed to produce these effects through the stimulation of 5-HT2A receptors in the brains cortex, which are ordinarily triggered by the brains joy chemical, serotonin.
These psychedelic compounds can be divided into two major categories: entheogens, which are psychedelic compounds originally derived from plants, and synthetically manufactured psychedelics. Common entheogens include psilocybin, which is the active component in magic Psilocybe mushrooms, and ibogaine, a psychoactive compound found in the bark of the Tabernanthe Iboga shrub native to Gabon. Synthetic psychedelics include the likes of LSD, MDMA, and ketamine.
Both entheogens and synthetically developed psychedelics are of increasing interest to researchers, who believe that their ability to modulate serotonin activity could be useful in the treatment of mood disorders and other mental health conditions.
As the Psychedelics as Medicine Report details, there have been a number of active and past clinical trials investigating the use of psychedelics in treating cluster headaches, pain, arthritis, and other physical health problems. However, where research has demonstrated the most promise is in the treatment of mental health disorders.
The primary focus of psychedelics as medicine has become the treatment of post-traumatic stress disorder (PTSD), major depressive disorders (MDD), and treatment-resistant forms of depression (TRD). Collectively, these conditions affect hundreds of millions of people worldwide and their prevalence continues to rise, making the promise of psychedelic therapeutics an ever more pertinent area of study.
. . . while there will undoubtedly be plenty of opportunity for investment, the focus of the industry must remain on the benefits that these products will bring to a rapidly growing patient base, and the creation of a legal and fully regulated field of medicine that is trusted, consistent and sustainable for the future. The Psychedelics as Medicine Report: First Edition.
Aided in part by the normalisation of researching other previously stigmatised drugs (e.g. cannabis) for medical purposes, many prestigious universities and research institutions such as Johns Hopkins, New York University, and the University of California, Los Angeles have now begun investigating psychedelics in a similar vein.
In the United States, research conducted by Compass Pathways and the Usona Institute has led to the psychedelics MDMA and psilocybin both being awarded breakthrough therapy designations from the US Food and Drug Administration (FDA), in recognition of their promise in treating PTSD and MDD/TRD respectively. The designation allows for the development and review process for research on these psychedelics to be expedited, as they represent a substantial improvement in outcomes over existing therapies.
In February 1971, the United Nations published the Convention on Psychotropic Substances. The treaty officially designated most of the major synthesised psychedelics, including LSD, DMT, and MDMA, as internationally controlled substances. Later that same year, the United States and United Kingdom would bring in even stricter domestic controls on psychedelic compounds, including the plant-derived psilocybin/psilocin and mescaline psychedelics in their respective Schedule 1 and Class A controlled substance designations.
In the present day, a new decriminalisation/legalisation movement for psychedelics is gaining strength. In the Americas, religious rights battles have led to the legalisation of peyote and ayahuasca use in select Native American and indigenous tribes and religious communities, where the substances have been traditionally used in spiritual worship and healing ceremonies.
Several US states have previously, albeit unsuccessfully, sought to decriminalise the medicinal use of psilocybin; though a campaign group in Oregon is currently actively lobbying the state to make psilocybin available for medicinal use in 2020. These campaigns, taken in conjunction with the FDAs recent breakthrough therapy designations make the United States a key area to watch for medical psychedelics.
Brazil and Jamaica are also establishing themselves as key areas for psychedelics research. Brazil is one of the leaders in research output for the potential applications of ayahuasca within neuroscience, with major psychedelics research groups based at the Federal University of Rio Grande do Norte, the University of So Paulo, and the Chacruna Institute.
In Jamaica, psychedelics have never explicitly been made illegal. This has allowed the nation to open the worlds first psilocybin mushroom research centre, which is based at the University of the West Indies in Mona. The centre, which is funded by the Canadian psychedelics company Field Trip Ventures, plans to study the genetics of the Psilocybe mushrooms to develop improved methods of psilocybin extraction which they then hope to patent and commercialise.
To learn more about psychedelics as medicine, and the future medical and commercial potential of the field, download The Psychedelics as Medicine Report: First Edition, here.
See the original post here:
- Researchers looking to treat depression with psychedelic mushrooms - Wisbusiness.com - August 26th, 2020
- Wall Street donors are racing to back psychedelic therapy - Quartz - August 26th, 2020
- MindMed, Liechti Lab to Study Effects of Combining LSD, MDMA - Psych Congress Network - August 26th, 2020
- Canadian Government Will Respond To Psychedelics Decriminalization Petition - Marijuana Moment - August 26th, 2020
- Son of the White Mare Review: The Greatest Psychedelic Animated Movie Ever Made - IndieWire - August 26th, 2020
- Congressman advocates for the legalization of psilocybin therapy - The GrowthOp - August 26th, 2020
- An Introduction to Psychedelics in Marketing - Adweek - August 20th, 2020
- Psychedelic drugs reduce depressive symptoms by helping individuals accept their emotions, study suggests - PsyPost - August 20th, 2020
- Tripping on Ayahuasca has always been fun, but now it might be good for you - GOOD Magazine - August 20th, 2020
- From pot to shrooms: What's next for decriminalization? - The GrowthOp - August 20th, 2020
- Are NDEs caused by carbon dioxide overload? And what about psychedelics? - Patheos - June 24th, 2020
- ATAI dives into digital therapeutics to boost mental health care - FierceBiotech - June 24th, 2020
- 'People Should Have the Fundamental Right To Change Their Consciousness' - Reason - June 24th, 2020
- Revive Therapeutics betting on psychedelics and potential COVID-19 treatment Bucillamine - Proactive Investors USA & Canada - June 20th, 2020
- These Psychedelic Drugs May Be Key to Revolutionizing Weight Loss Treatment - Yahoo Finance - June 20th, 2020
- Champignon Brands CEO Dr Roger McIntyre authors studies appearing in two leading scientific journals - Proactive Investors USA & Canada - June 20th, 2020
- The effects of psychedelics on the brain's "consciousness conductor" - New Atlas - June 17th, 2020
- Psilocybin Dulls Activity in Brain Region Linked With Consciousness - Psych Congress Network - June 17th, 2020
- Champignon Brands revamps its brand identity to better reflect its scientific focus on psychedelic medicine - Proactive Investors UK - June 17th, 2020
- Mota Ventures Appoints Roger C. Clinton as Member of Advisory Board to Verrian GmbH - Its Psilocybin Research Subsidiary - Stockhouse - June 17th, 2020
- Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week - Yahoo Finance - June 13th, 2020
- New Psychedelics Stocks and Acquisitions | 2020-06-08 | Investing News - Stockhouse - June 13th, 2020
- Pure Extracts: The Second Wave of Psychedelic Operators - The Deep Dive - June 13th, 2020
- New analysis claims the FDA rushed ketamine's approval for depression treatment - Big Think - June 13th, 2020
- How Liv Vasquez Uses Plants & Food for Wellness and Healing - Thrillist - June 13th, 2020
- Companies are starting to bet big on psychedelic drugs to treat US mental health epidemic - Proactive Investors USA & Canada - June 6th, 2020
- CHECK IT OUT: New from Lady Gaga; take a wild ride; beach reading; and a screen gem - Wicked Local - June 6th, 2020
- Dr. Bronner's Soaps Wants to Protect You From COVIDand Legalize Your Right to Magic Mushrooms - Mother Jones - June 6th, 2020
- 6 celebrities wildest psychedelic trips, as told by themselves - Insider - INSIDER - June 1st, 2020
- Rate and Review: Have a Good Trip - The Independent Florida Alligator - June 1st, 2020
- First-of-Its-Kind Study Hints at How Psilocybin Works in The Brain to Dissolve Ego - ScienceAlert - June 1st, 2020
- Codebase says psychedelic investee Red Light Holland debuts on CSE with ticker TRIP - Proactive Investors USA & Canada - June 1st, 2020
- Todd Shapiro of Red Light Holland on 'magic truffles' and the multi-billion dollar psychedelics market - InvestorIntel - June 1st, 2020
- This Trippy Oregon Theme Park Is A Low-Key Psychedelic Playground - Thrillist - May 15th, 2020
- EGF Theramed Appoints George Anstey to Board of Directors - Benzinga - May 15th, 2020
- Empower Clinics and EuroLife Brands Close Definitive Agreement and Sign Multi-Year Multi-National Licence Agreement - GuruFocus.com - May 15th, 2020
- Have a Good Trip Demystifies Psychedelics - The New Republic - May 14th, 2020
- Investing in Psychedelics - Energy and Capital - May 14th, 2020
- Psilocybin May be the Key to Treating a Range of Health Issues, Including Obesity - Baystreet.ca - May 14th, 2020
- Movie review: Netflix's 'Have a Good Trip' is only a mild high - Eagle-Tribune - May 14th, 2020
- Psychedelics - Alcohol and Drug Foundation - May 10th, 2020
- Celebrities share LSD trips in Netflix documentary 'Have A Good Trip' - Insider - INSIDER - May 10th, 2020
- The Queen of Consciousness Driving Psychedelic Study and Advocacy - Filter - May 10th, 2020
- The 'Billions' Stock Watch: It's Time For Psychedelics And Subterfuge - UPROXX - May 10th, 2020
- Have a Good Trip: Netflix release and cast as celebrities recall mind-bending experiences - Mirror Online - May 10th, 2020
- From "Solar Opposites" to "Midnight Gospel," recent otherworldly animation is worth the head-trip - Salon - May 10th, 2020
- Netflix Reveals Celebrities' Wildest Drug Trips, From Anthony Bourdain to Carrie Fisher - The Daily Beast - May 10th, 2020
- Psychedelic mushrooms for depression: 'This is the one that changed things' - DW (English) - April 26th, 2020
- MindMed wants to develop a drug to help end a bad LSD trip - Fast Company - April 26th, 2020
- Netflixs The Midnight Gospel Is a Profoundly Weird Psychedelic Trip You Want To Take - Mashable India - April 26th, 2020
- Professor describes uses and history of hallucinogens - The Daily Evergreen - April 26th, 2020
- Media Central moves to provide coverage on emerging Psychedelics and eGames sectors - Proactive Investors USA & Canada - April 26th, 2020
- This video game does the same things to your brain as magic mushrooms - Happy Mag - April 26th, 2020
- Inborn Psychedelia on White Nights' Into the Lap of the Ancient Mother - Invisible Oranges - April 26th, 2020
- Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week - Yahoo Finance - April 9th, 2020
- Psychedelic mushrooms could affect the brain long after its active ingredient leaves the system - The Next Web - April 9th, 2020
- We Could Be Taking Psychedelics to Help Treat Mental Illness in Just Five Years - Newsweek - April 7th, 2020
- Magic mushrooms to treat depression? COMPASS Pathways pushes forward with U.S. patent for psilocybin therapy - Straight.com - April 7th, 2020
- Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week - Benzinga - March 18th, 2020
- With No Progress in Therapy, NYC Couple Turns to Psychedelics for Help - NBC New York - March 13th, 2020
- Upscale Psychedelics Therapy Center Opens On New Yorks 5th Avenue - Forbes - March 13th, 2020
- Why Kevin O'Leary is betting on psychedelics - Wealth Professional - March 13th, 2020
- Learning the hard way that psychedelic drug use can have long-term consequences - Dailyuw - March 13th, 2020
- Forget taking a pill a day. Canada is using psychedelics to revolutionize the way we treat mental health and addiction - The GrowthOp - March 13th, 2020
- High Stakes: Will The Legalization Of Psychedelics Mimic That Of Cannabis? Will It Learn From Its Mistakes? - Benzinga - March 13th, 2020
- Scientists Just Proved These Two Brain Networks Are Key to Consciousness - Singularity Hub - March 13th, 2020
- Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week - MarketWatch - March 13th, 2020
- Podcast Host Joe Rogan Is Steadily Documenting A Psychedelic Record Of The 21st Century - Forbes - February 27th, 2020
- Empower Clinics to create psilocybin and psychadelics division leveraging corporate wellness and franchise clinic network - Proactive Investors USA... - February 27th, 2020
- The Psilocybin Movement Is Like The Cannabis Movement (Except When It's Not) - Benzinga - February 27th, 2020
- Researchers went to festivals to study psychedelic drugs and found they left people feeling happy and connected hours after the high wore off -... - January 22nd, 2020
- Psychedelics and Their 'Mystical Effects' in the Real World - Medscape - January 22nd, 2020
- Psychedelic Events Are Going Mainstream, Where The Much-Maligned Mushroom Industry Focuses On Mental Health - Forbes - January 18th, 2020
- Psychedelics have 'extraordinarily potent' anti-inflammatory power. Is there a place for them in mainstream medicine? - Genetic Literacy Project - January 18th, 2020
- Silicon Valley Is Micro-Dosing Magic Mushrooms To Boost Their Careers - Forbes - January 18th, 2020
- NYC To Host Economics Of Psychedelics Investing Summit - Benzinga - January 18th, 2020
- The Best FREE Things to Do for the Next Week - My New Orleans - January 18th, 2020
- Photos of the Stuff That Fascinates People While They're Tripping On LSD - VICE - January 18th, 2020
- Rats on DMT hint at the benefits of psychedelic microdosing - Inverse - December 31st, 2019
- BEYOND LOCAL: Would you ever consider psychedelics to treat PTSD? - SooToday.com - December 31st, 2019